Posts Tagged ‘Clinical and Safety’

Bring out the popcorn! This Thursday, Dr. Rodney Lemery, one of our experts in drug safety and pharmacovigilance, will be delivering a webinar on the latest version of Oracle Argus Safety, the most widely used and trusted PV system on the market. This presentation is meant for everyone, whether you’re already using the system and […]

  Demographics in clinical trials have always been scrutinized by the medical community and the public. Are various races, ethnicities, sexes, and ages fairly represented in trials? Does one segment respond better or worse than another to a particular treatment? These questions and more are being answered in the Drug Trials Snapshots section of the […]

  In a time when the turnover rate for clinical monitoring positions in the U.S. hovers around 25%, it’s more important than ever to do more with less. With risk-based monitoring (RBM), contract research organizations (CROs) and sponsors can leverage data in existing IT systems to spot, rectify, and prevent issues related to the execution […]

  Real-world data, the data generated about drugs and devices in real-world settings (e.g., routing doctor visits, hospital stays, etc.), can help develop more accurate product profiles. This is because the data comes from products that are no longer confined to the smaller, homogenous populations involved in clinical trials. More comprehensive profiles can help better […]

  Oracle’s third quarter 2016 earnings call was peppered with strong revenues and big wins in various categories. But what was most striking was the incredible progress the enterprise software powerhouse has made with regard to the cloud. Between CEO Safra Catz, CEO Mark Hurd (yes, they’re both CEOs), and Executive Chairman of the Board […]

  Perficient’s Life Sciences practice regularly monitors the software release notes for several Oracle Health Sciences applications, as well as our own clinical and safety systems. The systems covered in our review are: 

  Now that April is here, I thought it would be neat to look back at what our readers found most interesting last month. Below are the top five blog posts Perficient’s life sciences practice wrote in March – they’re ranked in order of popularity, with number one being the most viewed piece. 

  At the end of 2015, Austin Frakt, a health economist, researcher, and contributor to The New York Times’ The Upshot, wrote about the life sciences industry’s lack of interest in developing medicines that prevent cancer. 

  On January 14, 2016, Perficient hosted a webinar titled Leveraging Siebel CTMS for Risk-Based Monitoring. We received some good questions during the webinar and figured we’d share them (and the answers) with you. 

Medication non-adherence continues to be a big issue in the pharma industry, affecting clinical outcomes for both approved and investigational drugs. Sponsors, research organizations, and payers are looking to verify that what they’re studying or paying for is actually being used as directed. Various technologies, such as Proteus and AiCure, are being examined for these […]

  As we mentioned in our life sciences trends guide for 2016, patient recruitment is a constant challenge that needs to be confronted head-on with innovative tactics and technology. The mere fact that only 5% of cancer patients ever enroll in a trial is simply unacceptable, considering how connected we are in the digital era. 

  In “fun” news, the FDA wants to know if the use of animation in pharmaceutical advertising affects consumers’ general perception of drugs, as well as the side effects they can cause. According to a Notice posted on the Federal Register website, the FDA is looking to answer the following questions: